Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Nature Communications
Sarfaraz A HasniMariana J Kaplan

Abstract

Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In lupus animal models, the Janus kinase (JAK) inhibitor tofacitinib improves clinical features, immune dysregulation and vascular dysfunction. We conducted a randomized, double-blind, placebo-controlled clinical trial of tofacitinib in SLE subjects (ClinicalTrials.gov NCT02535689). In this study, 30 subjects are randomized to tofacitinib (5 mg twice daily) or placebo in 2:1 block. The primary outcome of this study is safety and tolerability of tofacitinib. The secondary outcomes include clinical response and mechanistic studies. The tofacitinib is found to be safe in SLE meeting study's primary endpoint. We also show that tofacitinib improves cardiometabolic and immunologic parameters associated with the premature atherosclerosis in SLE. Tofacitinib improves high-density lipoprotein cholesterol levels (p = 0.0006, CI 95%: 4.12, 13.32) and particle number (p = 0.0008, CI 95%: 1.58, 5.33); lecithin: cholesterol acyltransferase concentration (p = 0.024, CI 95%: 1.1, -26.5), cholesterol efflux capacity (p = 0.08, CI 95%: -0....Continue Reading

References

Sep 12, 1992·BMJ : British Medical Journal·P GompertzE Dickinson
Mar 25, 2000·Annals of the Rheumatic Diseases·G S DeanD A Isenberg
Dec 26, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Silvia N KariukiTimothy B Niewold
Feb 19, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael F DennyMariana J Kaplan
Mar 11, 2011·Science Translational Medicine·Gina S Garcia-RomoVirginia Pascual
Dec 2, 2011·The New England Journal of Medicine·George C Tsokos
Jan 11, 2013·The New England Journal of Medicine·John J O'SheaLouis M Staudt
Jun 1, 2013·The Journal of Clinical Investigation·Jason S KnightMariana J Kaplan
Sep 3, 2013·International Immunopharmacology·Krisztina FutosiAttila Mócsai
Jul 19, 2016·Arthritis & Rheumatology·Yasuko FurumotoMassimo Gadina
Nov 23, 2016·Rheumatology International·Konstantinos TziomalosPanagiota Boura
Jan 29, 2017·Arthritis & Rheumatology·Richard FurieUNKNOWN CD1013 Study Investigators
Mar 30, 2017·Clinical Science·Marc WeidenbuschHans-Joachim Anders
Jun 9, 2017·Journal of Hypertension·Peter WohlfahrtOndřej Sochor
Jun 14, 2017·Journal of Autoimmunity·Mayra Giannelou, Clio P Mavragani
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Oct 22, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Parésa L Taghavie-MoghadamElena V Galkina
Jun 6, 2018·Current Opinion in Rheumatology·Yudong Liu, Mariana J Kaplan
Jan 16, 2019·The Journal of Clinical Investigation·Richard FurieNathalie Franchimont
Jul 10, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Xiaoyang YangQingxia Wu
Aug 16, 2019·Lupus Science & Medicine·Monica M PurmalekMariana J Kaplan
Oct 24, 2019·Current Opinion in Rheumatology·Rishi R Goel, Mariana J Kaplan
Nov 15, 2019·Journal of Immunological Methods·Wanxia Li TsaiMassimo Gadina
Dec 19, 2019·The New England Journal of Medicine·Eric F MorandUNKNOWN TULIP-2 Trial Investigators

❮ Previous
Next ❯

Citations

Sep 2, 2021·Expert Review of Clinical Immunology·Shingo Nakayamada, Yoshiya Tanaka
Dec 3, 2021·Current Opinion in Hematology·Ofir Wolach, Kimberly Martinod

❮ Previous
Next ❯

Software Mentioned

JMP
Partek Genomics Suite
Excel
Nanostring
SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Australian Prescriber
Deutsche medizinische Wochenschrift
S DökerA El-Armouche
The New England Journal of Medicine
Roy FleischmannORAL Solo Investigators
© 2021 Meta ULC. All rights reserved